Mosunetuzumab IV step-up (8 cycles, 21-day; up to 17 if not in CR by C8) — r/r FL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-MOSUNETUZUMAB |
|---|
| ID | REG-MOSUNETUZUMAB-FL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-FL-2024 SRC-NCCN-BCELL-2025 |
Notes
GO29781 (Budde 2022): r/r FL after ≥2 prior lines (median 3 prior lines, 69% double-refractory) — ORR 80%, CR 60%, median DOR 22.8 mo, mPFS 17.9 mo. Time-limited (max 17 cycles) vs continuous BTKi. CRS predominantly cycle 1 step-up; Grade ≥3 ~2% — far below CAR-T. Cycle 1 hospitalization (for monitoring after step-up doses) standard; subsequent cycles outpatient. Ambulatory option vs CAR-T (one-shot, complex logistics) and tazemetostat (oral but lower CR rate). Boxed CRS warning, not BBW.
Used By
Indication
IND-FL-3L-MOSUNETUZUMAB- IND-FL-3L-MOSUNETUZUMAB